» Articles » PMID: 8646688

Expression of Tissue Factor Correlates with Grade of Malignancy in Human Glioma

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1996 May 1
PMID 8646688
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tissue factor (TF), a cell surface receptor of factor VII/VIIa, was initially recognized as an initiator of the extrinsic coagulation pathway. TF has recently been found to be expressed highly in certain types of malignant tumors. In addition, TF belongs to the interferon receptor family and is one of the immediate early genes, suggesting that TF may participate in the regulation of cell growth. However, the correlation between the expression of TF and cell growth is still unclear.

Methods: Expression of TF in 6 glioma cell lines and 44 glioma surgical specimens was studied by Northern blot analysis, Western blot analysis, immunohistochemistry, and in situ hybridization.

Results: Northern blot analysis showed that glioma cells expressed minor novel transcripts of 3.3 kb and 1.6 kb, in addition to the transcripts of 2.2 kb and 3.1 kb that were previously reported. Western blot analysis revealed that the level of TF protein did not correlate with that of TF transcripts. Although immunohistochemical analysis of surgical specimens showed that all gliomas were positive for TF, it was interesting that 1 of 10 benign gliomas (10%) was positive for TF (malignancy Grade I-II), 13 of 14 anaplastic astrocytomas (86%) (malignancy grade III) and 19 of 20 glioblastomas (95%) (malignancy grade IV) were moderately or strongly positive for TF. In situ hybridization showed the expression of TF mRNA in glioma cells.

Conclusions: TF is expressed in glioma and the level of expression correlates with the histologic grade of malignancy.

Citing Articles

Magnetic resonance imaging findings of intracranial extraventricular ependymoma: A retrospective multi-center cohort study of 114 cases.

Li L, Fu Y, Zhang Y, Mao Y, Huang D, Yi X Cancer Med. 2023; 12(15):16195-16206.

PMID: 37376821 PMC: 10469843. DOI: 10.1002/cam4.6279.


Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer.

Ahmadi S, Shabannezhad A, Kahrizi A, Akbar A, Safdari S, Hoseinnezhad T Biomark Res. 2023; 11(1):60.

PMID: 37280670 PMC: 10242999. DOI: 10.1186/s40364-023-00504-6.


Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.

Jo J, Diaz M, Horbinski C, Mackman N, Bagley S, Broekman M Neuro Oncol. 2023; 25(8):1381-1394.

PMID: 37100086 PMC: 10398809. DOI: 10.1093/neuonc/noad059.


The Heparan Sulfate Proteoglycan Syndecan-1 Triggers Breast Cancer Cell-Induced Coagulability by Induced Expression of Tissue Factor.

Hassan N, Buckreiss N, Efing J, Schulz-Fincke M, Konig P, Greve B Cells. 2023; 12(6).

PMID: 36980251 PMC: 10047229. DOI: 10.3390/cells12060910.


Hederagenin suppresses glioma cell biological activities via Nur77 in vitro study.

Dai Y, Masra N, Zhou L, Yu C, Jin W, Ni H Food Sci Nutr. 2023; 11(3):1283-1296.

PMID: 36911825 PMC: 10002964. DOI: 10.1002/fsn3.3163.